Main Uses of Elaspol

Elaspol, containing the active ingredient sivelestat sodium hydrate, is a therapeutic agent specifically designed to address acute lung injury associated with systemic inflammatory response syndrome (SIRS). It belongs to a class of medications known as selective neutrophil elastase inhibitors.

The primary clinical application of Elaspol is to improve pulmonary function in patients experiencing acute respiratory distress. By targeting the underlying inflammatory mechanisms that lead to lung tissue damage, the medication helps manage the severity of respiratory failure in critical care settings.

Benefits and Mechanism of Action

Elaspol works by inhibiting neutrophil elastase, an enzyme released by white blood cells during intense inflammatory responses. In conditions like SIRS, the overproduction of this enzyme can lead to the degradation of elastic fibers and vascular damage within the lungs, resulting in impaired oxygen exchange.

Improvement of Respiratory Status

The administration of Elaspol is intended to achieve the following clinical benefits:

• Reduction of Pulmonary Inflammation: By neutralizing excessive neutrophil elastase, the medication helps limit the progression of inflammatory damage to the alveolar-capillary membrane.
• Shorter Duration of Mechanical Ventilation: Effective management of lung injury can assist in stabilizing the patient's breathing, potentially reducing the total time required for assisted ventilation.
• Enhanced Oxygenation: By protecting the integrity of lung tissue, the medication supports the lungs' ability to transfer oxygen into the bloodstream more efficiently.

Targeted Pathophysiology

Unlike broad-spectrum anti-inflammatory drugs, Elaspol is highly selective. It focuses specifically on the elastase enzyme, which allows it to address a key driver of acute lung injury without broadly suppressing the entire immune system's ability to respond to other challenges.

Elaspol (Sivelestat sodium hydrate) is approved for use in adult patients who have been diagnosed with Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS), provided that the condition is accompanied by Systemic Inflammatory Response Syndrome (SIRS).

Contraindications and Restrictions

The medicine is contraindicated in patients with a known hypersensitivity to Sivelestat sodium hydrate or any of the product's components. The official regulatory labeling specifies additional restrictions and populations for whom use is not established:

Patient Group or Condition	Regulatory Status
Pediatric Patients (Under 18)	Safety and efficacy not established across all age groups.
Pregnant Women	Not recommended unless therapeutic benefit outweighs possible risks.
Breastfeeding Women	Not recommended; use should be avoided as the substance is known to be excreted in breast milk.
Four or More Organ Failures (MOF)	Efficacy is not established; use is conditional.

Efficacy is also not established in patients with Acute Lung Injury resulting from specific causes, such as burns or trauma or severe chronic respiratory disease. The regulatory profile strictly defines the required patient eligibility and absolute exclusions for use.

Elaspol Interactions with other medicines and products

The interaction profile of Elaspol (Sivelestat sodium hydrate) is defined by the limited number of specific drug interactions formally documented in regulatory labeling from authoritative government sources, such as the Pharmaceuticals and Medical Devices Agency (PMDA).

---

Interaction Scope: Official Regulatory Status

Classification Area	Official Regulatory Documentation Status
Contraindicated Combinations	No medicinal products are explicitly listed as formally contraindicated for co-administration.
Metabolic Interactions (CYP Enzymes)	The official labeling does not specify Sivelestat as an inhibitor or inducer of Cytochrome P450 (CYP) enzymes, which are common mediators of drug interactions.
Transporter-Mediated Interactions	No interactions involving major drug transporters (e.g., P-gp) are explicitly documented in the official prescribing information.
Pharmacodynamic Interactions	No specific additive or synergistic effects with other therapeutic agents that necessitate a formal restriction are formally documented.
Food, Alcohol, or Herbal Products	No explicit restrictions or cautions regarding co-administration with food, alcohol, or herbal products are defined in the official regulatory documentation.
Timing-Based Rules	No mandatory administrative separation intervals are explicitly documented as an interaction requirement.

---

Summary of Official Interaction Statements

Official regulatory sources do not list specific medicines or product classes that lead to contraindicated combinations, required dosing separation, or predictable exposure modifications via standard metabolic or transporter mechanisms. The regulatory information, therefore, structures the interaction profile by the absence of explicit restrictions across the common categories of drug-drug and drug-substance interactions. This approach reflects the nature of Sivelestat as a specialized intravenous product used in acute care settings.

Elaspol (sivelestat sodium hydrate) acts through a pharmacodynamic mechanism focused on modulating specific enzymatic pathways involved in the acute inflammatory response.

Enzymatic Pathway Modulation

Elaspol functions as a selective inhibitor of human neutrophil elastase (HNE), a serine protease enzyme released by activated neutrophils. This activity constitutes an interaction within the mechanistic domain of enzyme-mediated signaling, modifying a critical molecular step in the proteolytic cascade.

---

Regulation of Proteolytic Activity

Inhibition of HNE by Elaspol modifies the enzyme's capacity for proteolytic degradation of components within the extracellular matrix. This action restricts the catalytic potential and subsequent destructive consequences associated with elevated neutrophil elastase activation.

---

Influence on Inflammatory Cascades

HNE contributes to inflammatory signaling by cleaving and activating various mediators and receptors. Suppression of HNE influences the subsequent activation steps within these inflammatory signaling pathways, thereby affecting the downstream regulation of pro-inflammatory factors.

How to Use Elaspol: Administration Guidelines

Elaspol (Sivelestat sodium hydrate) is provided as a sterile powder for injection, and its administration follows a specific protocol. All usage instructions relate to the management of acute conditions in a highly monitored setting.

---

Administration Scope

Feature	Guideline
Route of administration	Strictly Intravenous (IV) Infusion.
Dosing schedule	Administered at a continuous rate of 0.2 mg/kg/hour (milligrams per kilogram per hour), calculated based on the patient's body weight.
Preparation requirements	The powder must be reconstituted and diluted, typically with physiological saline (e.g., 0.9% sodium chloride injection).
Age-group rules	The regimen is standardized for adults and is weight-based.
Special procedural conditions	The infusion must be delivered at a constant, controlled rate and is limited to a maximum duration of 14 consecutive days.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Intravenous (IV) Infusion.
Frequency pattern	Continuous Infusion (24 hours per day).
Use-context constraints	Requires a highly monitored medical setting for continuous, controlled IV delivery.

---

Resulting Procedural Structure

Step sequence:

• The Elaspol powder is reconstituted and diluted into the final solution for infusion.
• The patient's body weight is used to calculate the required 0.2 mg/kg/hour rate.
• The solution is administered via a continuous intravenous infusion at the calculated steady rate.
• Administration is maintained for a short-term course, not to exceed 14 days.

Connection to the overall use protocol: The instructions establish that Elaspol is a medication requiring precise, weight-based control and delivery directly into the bloodstream. This protocol governs the medicine's use as a short-term, continuous treatment in the acute care environment, defining the route, dose rate, and maximum period of administration.

Research Evidence / Overview of Studies for Elaspol

Elaspol (Sivelestat) was studied for use in critically ill patients, with the goal of understanding how it was associated with changes in patient outcomes. The research has centered on conditions related to acute lung injury and systemic inflammation. Research provides context but not individual predictions.

---

Research Evidence for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS)

The main research exploring Elaspol has focused on its use in adults in the intensive care unit (ICU) who have Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS), especially when these conditions are linked to a Systemic Inflammatory Response Syndrome (SIRS) or sepsis.

The research primarily involved short-term Randomized Controlled Trials (RCTs), where patients were randomly assigned to receive either Elaspol or a placebo (an inactive substance) alongside standard care. Other evidence includes large systematic reviews, meta-analyses, and post-marketing observational studies.

Study Endpoints: What Researchers Measured

These research settings used in research exploring how symptoms change over time by focusing on objective, measurable endpoints. The primary clinical outcomes that studies monitored included 28-day survival rates. Researchers also monitored outcomes related to systemic or functional imbalance, such as the patient's duration of mechanical ventilation (MV) and the number of days the patient was alive and free from a ventilator. Studies also examined how the Oxygenation Index—a measurement of how well the lungs transfer oxygen to the blood—changed during the first week of treatment.

The findings describe patterns observed in the studies regarding these physiological markers. For instance, data from some regulatory-mandated studies show patterns related to changes in the Oxygenation Index measured earlier in the study period compared to control groups during the initial acute phase. Similarly, some trials monitored outcomes related to the duration of mechanical ventilation and ventilator-free days when compared to groups receiving a placebo. However, research does not determine whether an individual will respond similarly.

---

What Remains Uncertain and Research Gaps

Despite the research that has been conducted, evidence is limited in key areas, and there are recognized gaps in the evidence landscape for Elaspol.

The most significant gap relates to the primary outcome that was studied for 28-day survival, as results were observed to be inconsistent across the international body of RCTs. Furthermore, the populations studied for this medicine was observed in contexts where the patients already had varying severity levels and different underlying causes of their lung injury; studies note this high patient heterogeneity. This variability makes it difficult to draw uniform conclusions. Overall, the research is ongoing to provide a clearer and more consistent understanding of the findings across all potential patient groups.

Common questions about Elaspol (FAQ)

Q: Can Elaspol be taken at the same time as common over-the-counter painkillers?

Regulatory documents do not list non-prescription painkillers as strictly forbidden (contraindicated) for use with Elaspol. However, official information notes that cautions may exist when combining it with other anti-inflammatory agents or medicines that affect blood clotting. The potential for an increased bleeding risk is a factor that clinicians take into account.

Q: How quickly can a person expect to notice the effects of Elaspol?

According to the official product information, Sivelestat sodium hydrate generally begins to exert its effects relatively quickly after the continuous infusion is started. Clinical summaries indicate that the effects are often noticed within a few hours of administration.

Q: Can older adults typically use Elaspol?

Elaspol is administered to adults in acute care settings. However, official safety notes indicate that a potentially elevated risk was observed in a specific subgroup of older adults aged 80 years or older. This is information for medical teams to consider.

Q: Do any official documents describe Elaspol as potentially affecting driving or operating machinery?

Regulatory safety data notes that some patients experience potential neurological side effects, which can include dizziness and confusion. Since this medicine is administered in a hospital setting, these effects are addressed within the standard care provided by clinicians.

Q: Is Elaspol considered a specialty medicine or is it widely available?

Elaspol is a specialized, synthetic injectable product, which is supplied as a powder for reconstitution. Official administration guidelines define its use as a continuous intravenous (IV) infusion, requiring delivery in a highly monitored acute care setting.

Q: Can I use Elaspol if I have existing liver or kidney concerns?

The use of Elaspol is not recommended in patients who have severe hepatic (liver) impairment. Furthermore, official guidance specifies monitoring of both kidney and liver function during the course of treatment to manage any potential adverse effects on these organs.

Q: Has Elaspol been approved in many countries, and is the research consistent?

Sivelestat is approved for use in Japan, but regulatory records indicate it is not approved in the United States. Research has shown that results regarding the primary clinical outcome of 28-day survival were observed to be inconsistent across international clinical trials.

Q: Is the main benefit of Elaspol an improvement in symptoms or preventing disease progression?

Research studies examining Elaspol measured both symptom-related effects, such as the improvement in the Oxygenation Index, and critical outcome markers. These critical outcomes, such as 28-day survival rates, relate to the patient's overall progression or recovery from the acute condition.

Q: What should a person do if they suspect an allergic reaction to Elaspol?

The official safety information notes the risk of serious adverse reactions, including life-threatening allergic reactions. The risks documented include events that necessitate prompt medical attention.

Q: What information is available about potential long-term risks associated with Elaspol?

The administration of Elaspol is strictly limited to a maximum duration of 14 consecutive days, meaning it is a short-term treatment. The safety profile also includes an observed signal regarding potentially increased long-term mortality in a specific clinical trial setting.

Q: Is there a generic version of Elaspol available, or is it only a brand name?

Sivelestat sodium hydrate is sold under the brand name Elaspol in approved regions. The specific regulatory status of a generic equivalent is not detailed in general summaries.

Q: Are there different strengths of Elaspol, and what does that mean?

Elaspol is supplied as a powder for reconstitution, and different commercial vial sizes (such as 10 mg or 50 mg) are available. However, the official administration protocol defines a single, continuous, weight-based rate for the infusion itself.

Q: Does Elaspol interact with common vitamins or mineral supplements?

Official regulatory documentation defines the interaction profile by the absence of explicit restrictions. There are no specific restrictions or cautions defined regarding co-administration with common vitamin or mineral supplements.

Q: Can people with a history of heart conditions use Elaspol?

Official information advises caution for patients with pre-existing conditions such as severe cardiovascular (heart) disorders. The need for careful monitoring is noted in the regulatory information.

Q: Are there specific official safety warnings related to long-term use of Elaspol?

The administration is limited to a maximum duration of 14 consecutive days, which limits the treatment to short-term use. Additionally, the safety data contains an observed signal regarding potentially increased long-term mortality.

Q: What are the legal or official uses for Elaspol in my country?

Sivelestat is approved for use in adult patients with Acute Lung Injury and Systemic Inflammatory Response Syndrome in certain countries, such as Japan. Regulatory approval and specific labeling may differ based on the country's governing health authority.

Q: Does taking Elaspol affect the results of typical blood tests?

Regulatory guidance specifies that blood parameters are monitored during treatment. Potential adverse effects include thrombocytopenia, which is a lower-than-normal platelet count that would be detected through blood tests.

Q: What are the most common reasons patients stop taking Elaspol?

Administration is limited to a maximum duration of 14 consecutive days. Patients may also stop if they meet any of the defined contraindications, such as a known hypersensitivity, or ineligibility criteria for use.

Q: Does Elaspol carry a 'Boxed Warning' or equivalent serious advisory in official documents?

Official safety information highlights serious risks, including gastrointestinal bleeding and life-threatening allergic reactions. It also notes a signal of potentially increased long-term mortality.

Q: Is there any public debate or controversy surrounding the research on Elaspol?

The research evidence notes that results regarding the 28-day survival endpoint were observed to be inconsistent across the international body of clinical trials. This factual inconsistency has been a subject of research discussion.

The storage and disposal of Elaspol (sivelestat sodium hydrate, an injectable powder) must strictly follow the conditions defined in regulatory labeling to maintain product quality.

Storage Requirements

• Temperature and Protection: The unopened vials must be stored at Controlled Room Temperature (typically up to 30 C or 86 F) and must not be frozen. The product must be kept in its original container and protected from light and moisture.
• Stability After Preparation: Once the powder is reconstituted for infusion, the prepared solution has limited in-use stability and must be used promptly or within the time limit specified by the regulator (e.g., 8 hours at 25 C). The medicine must also be stored out of the sight and reach of children.

Disposal Instructions

• Any unused or expired product must be disposed of in accordance with local and institutional requirements for pharmaceutical waste. Do not dispose of Elaspol through wastewater or household trash.